全文获取类型
收费全文 | 74880篇 |
免费 | 4630篇 |
国内免费 | 1883篇 |
专业分类
耳鼻咽喉 | 527篇 |
儿科学 | 1697篇 |
妇产科学 | 1101篇 |
基础医学 | 6736篇 |
口腔科学 | 1388篇 |
临床医学 | 7174篇 |
内科学 | 8522篇 |
皮肤病学 | 770篇 |
神经病学 | 4223篇 |
特种医学 | 1813篇 |
外国民族医学 | 6篇 |
外科学 | 8229篇 |
综合类 | 13041篇 |
现状与发展 | 3篇 |
一般理论 | 4篇 |
预防医学 | 6671篇 |
眼科学 | 1179篇 |
药学 | 6981篇 |
149篇 | |
中国医学 | 8735篇 |
肿瘤学 | 2444篇 |
出版年
2023年 | 1184篇 |
2022年 | 2058篇 |
2021年 | 2990篇 |
2020年 | 2828篇 |
2019年 | 3266篇 |
2018年 | 2762篇 |
2017年 | 2537篇 |
2016年 | 2262篇 |
2015年 | 2075篇 |
2014年 | 4672篇 |
2013年 | 4184篇 |
2012年 | 4250篇 |
2011年 | 5038篇 |
2010年 | 4505篇 |
2009年 | 3466篇 |
2008年 | 3134篇 |
2007年 | 3371篇 |
2006年 | 3145篇 |
2005年 | 2588篇 |
2004年 | 2120篇 |
2003年 | 2011篇 |
2002年 | 1423篇 |
2001年 | 1220篇 |
2000年 | 990篇 |
1999年 | 884篇 |
1998年 | 710篇 |
1997年 | 645篇 |
1996年 | 546篇 |
1995年 | 587篇 |
1994年 | 534篇 |
1993年 | 427篇 |
1992年 | 388篇 |
1991年 | 374篇 |
1990年 | 323篇 |
1989年 | 306篇 |
1988年 | 321篇 |
1987年 | 253篇 |
1986年 | 264篇 |
1985年 | 641篇 |
1984年 | 751篇 |
1983年 | 550篇 |
1982年 | 648篇 |
1981年 | 625篇 |
1980年 | 558篇 |
1979年 | 580篇 |
1978年 | 478篇 |
1977年 | 418篇 |
1976年 | 382篇 |
1975年 | 292篇 |
1974年 | 254篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的 探讨右美托咪定联合综合体温保护对腔镜手术治疗老年恶性肿瘤患者苏醒期质量及免疫功能的影响。方法 选择择期行腔镜手术治疗的老年恶性肿瘤患者90例,随机均分为3组:对照组(C组)、体温保护组(T组)和体温保护联合右美托咪定组(T-D组),每组30例。C组常规体温保护,T组和T-D组综合体温保护;T-D组麻醉诱导前10 min泵注右美托咪定0.5 μg/kg。记录3组患者麻醉诱导开始时(T0)、手术开始30 min(T1)、60 min(T2)、90 min(T3)、120 min(T4)以及手术结束时(T5)的鼻咽温度;于T0、术后2 h(T6)、24 h(T7)和48 h(T8)时抽取静脉血标本,测定T淋巴细胞亚群(CD3+、CD4+和CD8+)和自然杀伤细胞(NK cell)水平;记录患者术中麻醉药物用量及苏醒期质量指标。结果 与T0比较,C组T2~T5时点鼻咽温度均明显降低(P < 0.05);与C组比较,T组和T-D组T2~T5时点鼻咽温度明显升高(P < 0.05)。与T0时点比较,C组、T组和T-D组T6、T7和T8时点CD3+和NK cell活性均明显降低(P < 0.05);C组在T6、T7和T8时点,T组和T-D组在T6和T7时点,CD4+活性均明显降低(P < 0.05)。与C组比较,T组和T-D组T6和T7时点CD3+细胞活性均明显升高(P < 0.05);T组在T7时点,T-D组在T6和T7时点,CD4+细胞活性均明显升高(P < 0.05);T组在T7时点,T-D组在T6、T7和T8时点,NK cell活性均明显升高(P < 0.05)。结论 采用体温保护措施联合右美托咪定能够维持老年恶性肿瘤患者的体温稳定,减少围手术期意外低体温(IPH)的发生,并有效提高患者苏醒期质量,减轻免疫抑制程度,加速患者早期恢复。 相似文献
3.
4.
5.
6.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
7.
目的:对中药保质期或有效期进行系统的调研,探讨中药饮片设定保质期或有效期的依据及其必要性,为提高中药饮片质量、保障临床用药安全提供技术支撑,为药品监管部门制定有关法规提供科学依据。方法:以国家知识基础设施数据库(CNKI)为数据来源,采用文献计量学研究方法,选用检索词为“中药材”并“有效期”“饮片”并“有效期”,“饮片”并“保质期”“中药材”并“保质期”“中药材”并“效期”和“饮片”并“效期”,利用CNKI平台工具以及Excel统计工具进行统计分析。结果:经数据库检索、筛选,获取中药材、饮片保质期或有效期或效期的相关有效文献共85篇,其中关于中药、饮片保质期的相关文献26篇,中药、饮片有效期或效期的相关文献59篇;在59篇关于中药有效期的文献中,74.58%的文献对于中药是否应该制定有效期、如何制定有效期等展开了讨论,25.42%的文献为中药有效期研究的实验性文献。结论:本文从中药材、饮片保质期与有效期的现状,质量评价指标,研究方法,饮片分类、保质期制定的必要性,及其存在的问题和建议等方面进行了梳理和归纳,为中药饮片保质期制定,提供了详实的文献依据。 相似文献
8.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
9.
10.